Loading stock data…
$7.17+0.34 (+5.01%)
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States.
Immatics N.V. in the Healthcare sector is trading at $7.17 with a market capitalization of $1.3B. Wall Street consensus targets $17.63 (6 analysts), implying a +145.9% move over the next 12 months. The stock is currently near its 52-week low of $6.80, remaining 26.4% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $9.14M↑ | $7.61M↓ | $19.76M↑ | $5.19M↑ | $4.74M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$67.20M↓ | -$66.06M↓ | -$38.88M↑ | -$54.63M↓ | -$53.13M |
| Net Income | -$62.49M↓ | -$57.81M↓ | -$35.70M↑ | -$50.55M↑ | -$70.35M |
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies wi...